$BIOT

Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) was appointed as CelSiege Biosciences' authorized representative for IN01, a clinical-stage cancer immunotherapy, in Japan and China. BIOT will facilitate discussions on potential partnerships and investments for IN01, which targets lung cancer and other indications. The global NSCLC therapeutics market is estimated at $38.49 billion in 2025, according to Fortune Business Insights.

Instinct Bio (NASDAQ:BIOT) secured a site in Jakarta for its GENREVER CLINIC, targeting a December 2026 opening. Subscription tiers are set at $400, $1,000, and $3,000 monthly. The company also announced product development plans with Invitrx Therapeutics and PT PARVA CANDELA, aiming for 2026 production starts.

Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) said its subsidiaries entered a Memorandum of Agreement with Invitrx Therapeutics, Inc. to expand GENREVER into the U.S. via a planned trademark license and U.S. GMP manufacturing, and to explore supplying exosomes and conditioned media for regenerative medicine initiatives in Indonesia. Definitive deals and regulatory approvals are pending.

Instinct Bio Technical Company Holdings Inc. (NASDAQ: BIOT) said it will launch GENRÊVER CLINIC in Indonesia, a subscription-model beauty clinic under its Japanese brand with a cancel-anytime membership structure. The company plans about $1 million to open five directly operated sites starting in Jakarta, Surabaya, Bandung, Medan and Bali, with Dr. Mario Damianus Daniel Hadinoto involved.

Instinct Bio (BIOT) shares fell 51.46% to $1.33 Tuesday and dropped another 20.30% in after-hours to $1.06. The Nasdaq-listed biotech completed a business combination with Relativity Acquisition Corp. It entered an indicative term sheet for an equity purchase facility to sell up to $150M of common stock over three years, priced near VWAP less a discount, to fund development and working capital.